We further confirmed that administration of an ADAM10 inhibitor, which would block both NLGN3 secretion and NLGN3-mediated CSPG4 shedding, also resulted in a significant decrease in tumor burden and proliferation rate in patient-derived glioma xenografts, as expected2 (Extended Data Fig. 4). The gene discussed is ADAM10; the disease is central nervous system cancer.